Citadel Advisors’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Citadel Advisors’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,650	Closed	-$3.96K	–	15684
2024 Q2	$3.96K	Sell	1,650 -1,063	-39%	-$3.77K	﹤0.01%	13526
2024 Q1	$13.3K	Buy	2,713 +1,913	+239%	+$9.59K	﹤0.01%	13304
2023 Q4	$3.34K	Buy	800 +265	+50%	+$2K	﹤0.01%	13606
2023 Q3	$7.92K	Buy	535 +367	+218%	+$6.74K	﹤0.01%	13233
2023 Q2	$4.89K	Buy	168 +88	+110%	+$2.72K	﹤0.01%	13555
2023 Q1	$1.86K	Buy	80 +77	+2,567%	+$2.08K	﹤0.01%	14239
2022 Q4	$36	Buy	+3	New	+$58	﹤0.01%	14794
2022 Q3	–	Sell	-400	Closed	-$8K	–	13864
2022 Q2	$8K	Buy	+400	New	+$8.87K	﹤0.01%	12635

Other funds holding ASLN

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's ASLN Position: Q3 2024 in Review

Citadel Advisors sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2024, closing a stake of 14,709 shares — an estimated $35.3K sold.

Citadel Advisors first reported a position in ASLN in Q4 2020 and held it in 15 quarters. The position peaked at $9.56M in Q2 2021. 1 fund tracked by Wall St. Rank holds ASLN as of Q3 2024.

Citadel Advisors reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2024 after selling out during the quarter.
Citadel Advisors sold 14,709 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2024, an estimated $35.3K.
Citadel Advisors first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2020 and held it in 15 quarters.
Citadel Advisors's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $9.56M in Q2 2021.
1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.